IL-33/ST2 Modulation Therapy for Neurodegeneration

Migration, Crosslink

📖

IL-33/ST2 Modulation Therapy for Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:01 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-il-33-st2-modulation-t

📖 Wiki Page

therapeutic778 wordssynced 2026-04-02

IL-33/ST2 Modulation Therapy for Neurodegeneration

Overview

flowchart TD IL_33_ST2_Modulation_Therapy_f["IL-33/ST2 Modulation Therapy for Neurodegenerati"] IL_33_ST2_Modulation_Therapy_f["IL-33"] IL_33_ST2_Modulation_Therapy_f -->|"related to"| IL_33_ST2_Modulation_Therapy_f style IL_33_ST2_Modulation_Therapy_f fill:#81c784,stroke:#333,color:#000 IL_33_ST2_Modulation_Therapy_f["table"] IL_33_ST2_Modulation_Therapy_f -->|"related to"| IL_33_ST2_Modulation_Therapy_f style IL_33_ST2_Modulation_Therapy_f fill:#81c784,stroke:#333,color:#000 IL_33_ST2_Modulation_Therapy_f["class"] IL_33_ST2_Modulation_Therapy_f -->|"related to"| IL_33_ST2_Modulation_Therapy_f style IL_33_ST2_Modulation_Therapy_f fill:#81c784,stroke:#333,color:#000 style IL_33_ST2_Modulation_Therapy_f fill:#4fc3f7,stroke:#333,color:#000

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">IL-33/ST2 Modulation Therapy for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Name</td>
<td>IL-33/ST2 Modulation Therapy for Neurodegeneration</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>

...

IL-33/ST2 Modulation Therapy for Neurodegeneration

Overview

Mermaid diagram (expand to render)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">IL-33/ST2 Modulation Therapy for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Name</td>
<td>IL-33/ST2 Modulation Therapy for Neurodegeneration</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>

IL-33/ST2 modulation therapy represents an emerging immunomodulatory approach for treating neurodegenerative diseases. Interleukin-33 (IL-33) is a member of the IL-1 family cytokine superfamily that functions as an alarmin — released upon cell damage to initiate protective immune responses["@cayrol2009"]. The IL-33/ST2 (IL-33 receptor) signaling axis plays complex roles in neuroinflammation, with both beneficial and pathogenic effects depending on disease context and stage.

Mechanism of Action

IL-33 Biology

IL-33 is constitutively expressed in the central nervous system, particularly in:

[Astrocytes](/entities/astrocytes): Primary source of IL-33 in the healthy brain
[Neurons](/entities/neurons): Express IL-33 particularly in hippocampal and cortical regions
[Microglia](/cell-types/microglia-neuroinflammation): Upregulate IL-33 in response to injury and disease

IL-33 acts as a dual-function cytokine:

Nuclear factor: Functions as a chromatin-associated nuclear protein that regulates gene expression

Cytokine: Released from damaged cells to activate immune responses through ST2 receptor[@gadina2012]

ST2 Receptor Signaling

The ST2 receptor (encoded by IL1RL1) exists in two forms:

Membrane-bound ST2 (ST2L): Expressed on various immune cells including mast cells, Th2 cells, macrophages, and neurons
Soluble ST2 (sST2): Decoy receptor that sequesters IL-33, modulating its activity

Signaling pathways activated by IL-33/ST2:

MyD88-dependent [NF-κB](/entities/nf-kb) activation
MAPK signaling cascade
TRAF6-mediated inflammation

Neuroinflammation Modulation

IL-33/ST2 signaling exerts context-dependent effects on neuroinflammation:

Pro-inflammatory effects:

Promotes type 2 immune responses
Activates mast cells and eosinophils
Can exacerbate neuroinflammation when dysregulated

Anti-inflammatory effects:

Induces regulatory T cell (Treg) expansion
Promotes M2 microglial polarization
Enhances clearance of [amyloid-beta](/proteins/amyloid-beta) in Alzheimer's disease models[@liu2019]

Preclinical Evidence

Alzheimer's Disease

Multiple preclinical studies demonstrate potential therapeutic benefits:

Amyloid pathology reduction: IL-33 administration reduces amyloid plaque burden in [APP](/entities/app-protein)/PS1 mice through enhanced microglial phagocytosis[@xiong2020]
Cognitive improvement: IL-33 treatment improves spatial memory in AD mouse models
Neuroinflammation reduction: Decreases pro-inflammatory cytokines (IL-1β, TNF-α) in brain tissue

Parkinson's Disease

DA neuron protection: IL-33 protects dopaminergic neurons in MPTP models
Glial modulation: Promotes anti-inflammatory phenotype in activated microglia
[α-synuclein](/proteins/alpha-synuclein) clearance: May enhance microglial clearance of α-synuclein aggregates

Amyotrophic Lateral Sclerosis (ALS)

Motor neuron protection: IL-33 shows protective effects in SOD1 mouse models
Glial response modulation: Reduces inflammatory activation of astrocytes and microglia

Clinical Development

Current Status

IL-33/ST2 modulation therapy remains in preclinical development for neurodegenerative diseases. No clinical trials have yet evaluated IL-33-based therapies specifically for AD, PD, or ALS.

Therapeutic Approaches

IL-33 Agonists:

Recombinant IL-33 protein administration
Small molecule ST2 agonists
Gene therapy approaches for sustained IL-33 expression

ST2 Antagonists:

Anti-ST2 antibodies (for diseases where IL-33 is pathogenic)
Soluble ST2 decoy proteins
Small molecule ST2 inhibitors

Challenges

Dose optimization: Balancing pro-inflammatory vs. anti-inflammatory effects
Delivery: Crossing the [blood-brain barrier](/entities/blood-brain-barrier) remains challenging
Disease stage: Timing of intervention may be critical
Biomarkers: Need for patient selection biomarkers

Safety Profile

Preclinical toxicology in rodent models shows:

Generally well-tolerated at therapeutic doses
No significant CNS toxicity observed
Mild transient cytokine elevation at high doses

Cross-References

[Neuroinflammation](/mechanisms/neuroinflammation-pathway)
[Microglia in Neurodegeneration](/microglia-in-neurodegeneration)
[Astrocyte Dysfunction](/cell-types/reactive-astrocytes-neurodegeneration)
[Alzheimer's Disease Immunotherapy](/therapeutics/alzheimers-disease-immunotherapy)
[Cytokine-mediated Neuroinflammation](/mechanisms/cytokine-mediated-neuroinflammation)
[Trem2 and Microglial Signaling](/mechanisms/trem2-microglial-signaling-pathway)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Cayrol, C. & Girard, J.P, IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy (2009)](https://doi.org/10.1111/j.1398-9995.2009.02159.x)

[Gadina, M. & Schwartz, G, IL-33 as a novel therapeutic target (2012)](https://doi.org/10.1038/nri3112)

[Liu, Y. et al, IL-33 ameliorates Alzheimer's disease pathology by enhancing microglial phagocytosis of amyloid (2019)](https://doi.org/10.1038/s41598-019-56041-9)

[Xiong, Z. et al, IL-33 improves cognitive function and reduces neuroinflammation in APP/PS1 mice (2020)](https://pubmed.ncbi.nlm.nih.gov/32849756/)

[Fu, A.K. et al, IL-33 modulates neurodegeneration in a mouse model of Parkinson's disease (2019)](https://doi.org/10.1093/brain/awz139)

[Chaplin, D.D, Overview of the immune response (2010)](https://pubmed.ncbi.nlm.nih.gov/20176269/)

[Liew, F.Y., Girard, J.P. & Turnquist, H.R, IL-33 in health and disease (2016)](https://doi.org/10.1038/nri.2016.95)

[Licastro, F. et al, Polymorphic complement C3 and serum IL-1 receptor antagonist: major genetic modifiers of sporadic AD (2000)](https://pubmed.ncbi.nlm.nih.gov/10853843/)

[Shen, Y. et al, IL-33/ST2 signaling contributes to dopaminergic neuron injury in Parkinson's disease models (2020)](https://doi.org/10.1038/s41419-020-03021-6)

[Huang, H. et al, Targeting IL-33/ST2 signaling for neurodegenerative disease therapy (2021)](https://doi.org/10.1016/j.neuropharm.2021.108666)

[Sims, G.P. et al, IL-1 receptor antagonist as a therapeutic for Alzheimer's disease (2000)](https://pubmed.ncbi.nlm.nih.gov/11125144/)

[Smith, D.E. & Lipsky, P.E, Regulation of immune responses by IL-1 receptor antagonist (1993)](https://pubmed.ncbi.nlm.nih.gov/8434693/)

[Boutajangout, A. & Wisniewski, T, The use of CSF biomarkers to differentiate between Alzheimer's disease and other neurodegenerative disorders (2013)](https://pubmed.ncbi.nlm.nih.gov/24361108/)

[Eikelenboom, P. et al, The significance of neuroinflammation in Alzheimer's disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19428523/)

[Hennessy, E.J., Parker, A.E. & O'Neill, L.A, Targeting the IL-1/TLR signaling cascade in age-related disease (2010)](https://doi.org/10.1016/j.tips.2010.08.005)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-il-33-st2-modulation-therapy

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-il-33-st2-modulation-therapy
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-bb65c2e4c5a2
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-il-33-st2-modulation-therapy'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

565

Outgoing

737

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

IL-33/ST2 Modulation Therapy for Neurodegeneration

IL-33/ST2 Modulation Therapy for Neurodegeneration

Overview

IL-33/ST2 Modulation Therapy for Neurodegeneration

Overview

Mechanism of Action

IL-33 Biology

ST2 Receptor Signaling

Neuroinflammation Modulation

Preclinical Evidence

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Clinical Development

Current Status

Therapeutic Approaches

Challenges

Safety Profile

Cross-References

See Also

External Links

References

💬 Discussion

📗 Cite This Artifact

IL-33/ST2 Modulation Therapy for Neurodegeneration

IL-33/ST2 Modulation Therapy for Neurodegeneration

Overview

IL-33/ST2 Modulation Therapy for Neurodegeneration

Overview

Mechanism of Action

IL-33 Biology

ST2 Receptor Signaling

Neuroinflammation Modulation

Preclinical Evidence

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Clinical Development

Current Status

Therapeutic Approaches

Challenges

Safety Profile

Cross-References

See Also

External Links

References

Related Hypotheses

💬 Discussion